RA0273

antibody from Oursmab

Targeting: GFRA3 GFRa-3

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0273

Provider

Oursmab

Product name

Nadecnemab (Biosimilar Reference Antibody) (GFRA3)

Antibody type

Monoclonal

Description

Nadecnemab is a human IgG4-kappa monoclonal antibody that specifically targets GFRA3 (GDNF family receptor alpha 3), a cell-surface receptor for the glial cell line-derived neurotrophic factor (GDNF) family. As an IgG4 isotype, it is designed to minimize effector functions (e.g., ADCC) and focus on receptor modulation. GFRA3 is involved in pain signaling and joint homeostasis. By binding to GFRA3, nadecnemab aims to inhibit its activation and downstream signaling pathways, thereby reducing pain and potentially modifying disease progression. It is being developed for the treatment of knee osteoarthritis (OA) and associated chronic pain.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.